Amryt Pharma Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Amryt Pharma Plc (AMYT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Amryt Pharma Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 223M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Peer revenue share: Amryt Pharma Plc accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AMYT Sales vs. its Competitors, Q4 2021
Amryt Pharma Plc generated 100.00 % of the combined sales of its peer group.
Amryt Pharma Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Amryt Pharma Plc | - | - | - | - |
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AMYT Stock Performance relative to its Competitors
AMYT Stock Performance relative to High-Confidence Competitors
Amryt Pharma Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Krystal Biotech Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Amryt Pharma Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.